Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models

Fig. 3

Predicted clinical efficacy beyond 18 months for EPI and 5–17 month cohorts for trials sites used for the fitting. Projections of clinical efficacy by site for the EPI cohort (orange) and 5–17 month cohort for follow-up longer than 18 months for trials sites used for fitting. Predictions are results of assuming vaccine parameters from model 18 (fit for half-life, site-specific variation and to both cohorts) and assuming site levels of exposure from adjusted transmission assumptions (ii). Black indicates mean estimates of trial data with 95 % CI for the EPI cohort and green for 5–17 month cohort, orange the model predictions for EPI cohort and purple model predictions for the 5–17 month cohort

Back to article page